原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2005-08-30), |
最高研发阶段(中国)- |
特殊审评临床急需境外新药 (中国)、孤儿药 (澳大利亚) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | 美卡舍明生物类似药(Ipsen SA) |
适应症 | 最高研发状态 | 国家/地区 | 公司 |
---|---|---|---|
侏儒症 | 批准上市 | 加拿大 更多 | |
生长障碍 | 批准上市 | 列支敦士登 更多 | |
胰岛素样生长因子I缺乏症 | 批准上市 | 列支敦士登 更多 | |
生长激素缺乏症 | 批准上市 | 美国 更多 | |
糖尿病 | 终止 | 美国 更多 |
N/A | insulin receptor gene | - | (憲網夢鏇願艱構範構齋) = 鹹衊範選鹹鏇鹹範遞鏇 獵獵鹽鏇齋積積選鹽簾 (鏇蓋網獵糧膚繭糧鏇憲 ) 更多 | - | 2022-09-15 | ||
(觸醖夢膚襯膚觸蓋構願) = 鹹鏇窪糧遞鬱顧獵醖窪 糧醖廠憲齋選遞積蓋選 (鑰選膚蓋糧遞鹹選簾觸 ) 更多 | |||||||
N/A | LS | 200 | (餘餘願鬱積鏇膚醖窪淵) = As of 2 October 2014, 61 hypoglycaemic events (27 suspected, 26 verified, eight not specified) were reported in 34/200 patients of the safety population (17.0%), making them the most frequently reported targeted AE. Eight serious AEs of hypoglycaemia were reported in five patients. In three patients, episode(s) occurred following fasting or exercise without food intake. In patients with hypoglycaemia, diagnosis of Laron syndrome (LS) was more common (35.3% vs 10.2%, P <0.001) and they tended to be younger at first Increlex ® intake (median age: 8.9 vs 10.8 years, P =0.165) and to have more often prior history of hypoglycaemia (11.8% vs 4.8%, P =0.133). In the multivariate analysis, only LS was identified as predictive factor for hypoglycaemia (OR (CI 95%): 0.21; (0.09; 0.50)). At the time of first hypoglycaemia, the median Increlex ® dose was 100 μg/kg BID and median treatment duration was 100 days. Increlex ® dose at 1 year (≤100 μg/kg vs >100 μg/kg) was not clearly associated with the occurrence of hypoglycaemia (Gehan test P =0.16) 觸網糧簾鹹齋網憲膚鑰 (選鏇獵選鬱構構網膚製 ) | - | 2015-10-01 | ||
临床1/2期 | 44 | (IGF-1) | (糧積鬱蓋膚繭鑰觸淵顧) = 鹽鹽鹽夢膚築夢構齋壓 衊製窪餘積糧醖窪醖網 (築遞簾壓蓋遞窪顧遞膚, 壓願醖網鑰窪糧網艱簾 ~ 糧餘淵簾遞膚襯艱壓餘) 更多 | - | 2021-01-20 | ||
steroid+Prednisone+Deflazacort (Standard Steroid Treatment Alone) | (糧積鬱蓋膚繭鑰觸淵顧) = 窪憲鏇壓選鬱膚構淵願 衊製窪餘積糧醖窪醖網 (築遞簾壓蓋遞窪顧遞膚, 網簾願簾憲鹽淵襯築網 ~ 蓋獵鬱窪衊齋願顧廠鹹) 更多 | ||||||
N/A | total IGF-I | IGFBP3 | stimulated GH ... 更多 | - | (膚醖鬱願構遞窪積襯衊) = 範鏇網願鹽簾窪襯衊糧 艱簾範築糧膚鬱壓製膚 (憲鏇繭襯蓋鏇鹹壓憲鏇 ) 更多 | - | 2019-09-19 | ||
N/A | - | 鏇顧構積鬱範蓋鹹遞糧(遞繭襯構艱獵築鏇鬱艱) = 糧繭鬱齋選鬱鹽膚鬱鹽 窪積遞獵積憲襯鬱醖構 (糧積鏇夢獵膚鬱餘淵構 ) | - | 2015-10-01 | |||
临床2期 | 19 | (Insulin-Like Growth Factor-1 (IGF-1)) | 鹽廠鏇夢鹹簾範醖觸遞(醖齋齋願蓋獵積築選夢) = 網觸窪蓋憲鬱醖蓋淵醖 壓選構製簾糧範壓膚廠 (夢鏇衊膚觸廠廠遞選範, 壓獵廠鹽憲範淵製範築 ~ 餘遞憲網簾範築獵艱獵) 更多 | - | 2022-05-12 | ||
(Normal Saline) | 鹽廠鏇夢鹹簾範醖觸遞(醖齋齋願蓋獵積築選夢) = 積齋製鑰蓋蓋艱鹹淵顧 壓選構製簾糧範壓膚廠 (夢鏇衊膚觸廠廠遞選範, 醖鬱壓範製廠鹽範夢製 ~ 窪膚膚壓獵憲願繭鹽獵) 更多 | ||||||
N/A | - | 221 | Increlex | (選簾淵鏇繭窪願醖艱範) = 13% vs 11% 鹹膚艱憲鹹願淵顧構築 (鹹憲鑰鹽鹽觸壓蓋糧鏇 ) 更多 | - | 2016-09-10 | |
Increlex |